



ASX ANNOUNCEMENT

Lumos Secures Two Service Agreements With Hologic

MELBOURNE, Australia (23 November 2022) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid point-of-care diagnostic technologies, is pleased to announce it has secured two new service agreements with Massachusetts-based women’s health company Hologic.

Hologic is a leading innovator in women’s health and has engaged Lumos to conduct two programs of work focused on the further development of a rapid, point-of-care test. The programs covered under these two agreements are expected to be completed by the middle of 2023, and Lumos is entitled to receive up to US\$1.5 million in revenue for the provision of its development services on these programs.

“We have had a long-standing commercial relationship with Hologic and are delighted to be awarded these two services agreements to assist with the development of their women’s health products,” said Doug Ward, CEO of Lumos Diagnostics. “I believe that strategic relationships which leverage Lumos’ IP and know-how are likely to be a critical component of Lumos’ business plans going forward, so it is particularly pleasing that Hologic has been sufficiently impressed with our previous work to award us these two new services agreements.”

This announcement has been approved by the Lumos Disclosure Committee

-Ends

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598